Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Engineering functionalized nanoparticles for HIV prevention
FY 2018-19
Summary
It has been more than 30 years since the discovery of HIV-1 as the cause of AIDS and so far, there are no vaccines that exists to prevent HIV-1 infection. The challenge in developing an HIV-1 vaccine is that the virus is immensely diverse and can evade our immune system’s responses. Broadly neutralizing antibodies (bNAbs) were recently discovered and individually, bNAbs can neutralize >90% of circulating HIV-1 isolates. Nevertheless, combining different bNAbs together in a single molecule, called bi-specific and tri-specific antibodies, can achieve near 100% neutralization with high potency. This breakthrough discovery has attracted considerable attention as bNAbs hold the promise of helping guide vaccine development, which can be used as a prophylactic against HIV-1.
The Julien lab has developed and patented a novel protein-based nanoparticle platform to multimerize antibody fragments that bind to antigens (Fabs). Using the Fab-nanaoparticle technology, I will genetically engineer a functionalized nanoparticle that combines up to 24 different Fab regions of bNAbs in a single antibody prophylactic. The nanoparticle will increase breadth of coverage with high potency to surpass the activity of bi-specific and even tri-specific antibodies. To effectively translate the technology as an injectable prophylactic for HIV-1 prevention pre-clinically, I must assess its half-life, biodistribution, toxicity and immunogenicity. The study involves designing, expressing and purifying a fully mouse-derived functionalized nanoparticle to test in mice. The results of this study will guide the development of a fully human-derived functionalized nanoparticle and this novel approach will transform the field of HIV-1 antibody vaccine development and help end the HIV/AIDS pandemic.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406520
Name
Nouanesengsy Amy
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Engineering functionalized nanoparticles for HIV prevention
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aids; Bi- And Tri-Specific Antibodies; Broadly Neutralizing Antibodies; Hiv-1; Immunology; Infectious Diseases; Nanoparticle; Platform Technology; Protein Engineering; Vaccine
Abstract
It has been more than 30 years since the discovery of HIV-1 as the cause of AIDS and so far, there are no vaccines that exists to prevent HIV-1 infection. The challenge in developing an HIV-1 vaccine is that the virus is immensely diverse and can evade our immune system’s responses. Broadly neutralizing antibodies (bNAbs) were recently discovered and individually, bNAbs can neutralize >90% of circulating HIV-1 isolates. Nevertheless, combining different bNAbs together in a single molecule, called bi-specific and tri-specific antibodies, can achieve near 100% neutralization with high potency. This breakthrough discovery has attracted considerable attention as bNAbs hold the promise of helping guide vaccine development, which can be used as a prophylactic against HIV-1.
The Julien lab has developed and patented a novel protein-based nanoparticle platform to multimerize antibody fragments that bind to antigens (Fabs). Using the Fab-nanaoparticle technology, I will genetically engineer a functionalized nanoparticle that combines up to 24 different Fab regions of bNAbs in a single antibody prophylactic. The nanoparticle will increase breadth of coverage with high potency to surpass the activity of bi-specific and even tri-specific antibodies. To effectively translate the technology as an injectable prophylactic for HIV-1 prevention pre-clinically, I must assess its half-life, biodistribution, toxicity and immunogenicity. The study involves designing, expressing and purifying a fully mouse-derived functionalized nanoparticle to test in mice. The results of this study will guide the development of a fully human-derived functionalized nanoparticle and this novel approach will transform the field of HIV-1 antibody vaccine development and help end the HIV/AIDS pandemic.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nouanesengsy, Amy
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~